x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

pharmaphorum Podcast

pharmaphorum is one of the leading global channels for insight into the pharma and healthcare industry – and is essentially a group of passionate people who like asking excellent questions. Our podcasts offer a chance to pose some of these questions to the keenest minds in our industry to look at the big issues and opportunities facing pharma, biotech and healthcare today. With interviews and contributions from a host of industry experts and insiders, the pharmaphorum podcast is a must-listen for

science life sciences

All Episodes

29:46

Policy in Focus: Trump’s MFN deals, FDA vouchers, and...

pharmaphorum Podcast ·

2025/11/07

At the end of September, President Trump invited Pfizer CEO Albert Bourla to the Oval Office to announce that the company and the administration had reached a "deal" on most-favoured nations drug pricing. This was followed by similar announcements from AstraZeneca and Merck. But are these deals substantive policy or PR sleight of hand?In today’s episode of the pharmaphorum podcast, host Jonah Comstock invites Hogan Lovells Partner Alice Valder Curran back to the show to help get to the bottom of

en-us

11:54

Biotech’s biggest challenge isn’t scientific, but...

pharmaphorum Podcast ·

2025/11/04

Amid historic advances in cell-based therapies and precision medicine, biotech’s biggest challenge isn’t scientific, it’s political. In a new pharmaphorum podcast, James Roosevelt Jr, a longtime healthcare leader, former associate commissioner of social security for retirement policy, and grandson of FDR, as well as Advisory Board Member for Pluri Inc, discusses regulatory bottlenecks and their stalling effect on cell-based therapies, as well as the real dynamics behind FDA reform, and why biotech

en-us

34:30

On targeted radiotherapeutics, with Marc Hedrick

pharmaphorum Podcast ·

2025/10/30

Radiation has for over a century been considered one of the most powerful methods of destroying cancer. But, even now, ways to deliver significant doses to a tumour without damaging normal surrounding tissue are few. And this is where targeted radiotherapeutics come in.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Marc Hedrick, president and CEO of Plus Therapeutics, a clinical stage pharmaceutical company developing targeted radiotherapeutics with advanced platform

en-us

12:28

Towards one, cohesive AI workflow: In conversation...

pharmaphorum Podcast ·

2025/10/28

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ilya Burkov, global head of healthcare & life sciences at Nebius, a company building one of the world’s leading AI infrastructure companies. Burkov discusses the deployment of AI and cloud-native infrastructure for improving the speed and indeed quality of drug development, as well as why access to compute not enough and how GenAI is helping pharma teams integrate real-world evidence into the pipeline. You can listen to episode

en-us

29:19

Collaborating on a connected platform journey, with...

pharmaphorum Podcast ·

2025/10/21

Bayer and Veeva have partnered for several years across commercial, R&D, and quality functions. But recently Bayer migrated to Veeva’s Vault CRM, taking that relationship, and Bayer’s connected platform journey, to the next level.In order to discuss this migration further, pharmaphorum spoke with Alexander Alex, head of Veeva Platform at Bayer, and Florian Schnappauf, vice president of enterprise commercial strategy at Veeva. Alex and Schnappauf explain how Vault CRM is a step-change for

en-us

14:28

ESMO25: Patient-centric oncological futures with...

pharmaphorum Podcast ·

2025/10/19

As pharmaphorum reported during ESMO 2025, fresh from a return to oncology with the FDA approval of zongertinib as a treatment for HER2-positive non-small cell lung cancer (NSCLC), tumour shrinkage observed by investigator review - Boehringer Ingelheim is racing to expand its label.As the company reported new data at the Congress from the phase 1b Beamion LUNG-1 study, underpinning the approval of zongertinib (Hernexeos) as a second-line therapy, web editor Nicole Raleigh spoke with Lykke Hinsch

en-us

30:30

Smoothing a contract pathway through uncertainty: In...

pharmaphorum Podcast ·

2025/10/16

Back in June, pharmaphorum spoke with Entity Risk’s CEO and co-founder, Neal Masia, a leading health economist, about the unknowns unfolding in the US following the commencement of the second Trump administration this year. Tune into today’s podcast for an exploration of the potential scenarios Masia mused might arise, as well as his insights on the 340B Program, PBMs, and risk-based contracts. You can listen to episode 210 of the pharmaphorum podcast in the player below, download the episode to

en-us

12:44

FH25: On the future of health, with Frontiers Health...

pharmaphorum Podcast ·

2025/10/14

In the final episode of our special Frontiers Health limited series of the pharmaphorum podcast, web editor Nicole Raleigh speaks with the Chairman of Frontiers Health, Robert Ascione. Ascione - a serial entrepreneur & thought leader in health innovation and digital health, global executive, CEO and founder of Healthware Group, and President of Health Innovation at EVERSANA – talks about his favourite memory from Frontiers Health, as well as how his work outside of the conference both informs

en-us

20:01

Allosteric small molecule therapies in PD, with Gene...

pharmaphorum Podcast ·

2025/10/09

As Gain Therapeutics announces positive Phase 1b results for its lead compound, GT-02287, pharmaphorum looks back to a conversation with the company’s CEO Gene Mack earlier in the year, discussing allosteric small molecule therapies in the Parkinson’s disease space.Mack discusses the company’s progress in this field, and explores where next in terms of the unmet needs of Parkinson’s disease and the potential of this specific area of R&D in the future. You can listen to episode 209a of

en-us

29:41

FH25: Jessica DaMassa on hosting, hype, and health...

pharmaphorum Podcast ·

2025/10/08

As one of Frontiers Health’s most recognisable faces (and voices), Jessica DaMassa, founder of WTF Health and long-time emcee of the conference, has had a front-row seat to the events evolution over the last decade. In this episode of the pharmaphorum podcast’s special Frontiers Health anniversary series, DaMassa joins Deep Dive editor, Eloise McLennan, for a behind-the-scenes look at what it takes to run the show – both on and off stage. She reflects on her very first visit to Frontiers Health, her

en-us

17:12

Improving ROI on AI investments and data quality,...

pharmaphorum Podcast ·

2025/10/07

Healthcare organisations are facing the simultaneous pressures of demonstrating ROI on AI investments, addressing clinician burnout, and satisfying compliance requirements. In a new pharmaphorum podcast, Dr Jay Anders, chief medical officer for Medicomp Systems, and also host of the Tell Me Where IT Hurts podcast, discusses why he believes that the only way organisations can solve all three of those problems is by first solving data quality issues. Anders talks about this data quality crisis, and

en-us

19:36

The importance of being disruption ready, with...

pharmaphorum Podcast ·

2025/10/03

The cell culture media industry is currently experiencing significant growth, driven by the increasing demand for biopharmaceuticals, advancements in tissue engineering, and the rising number of research activities in cell biology. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Brandon Pence, who was recently appointed President and COO of Fujifilm Biosciences, a company previously known as Fujifilm Irvine Scientific, about the cell culture media field. Pence also discusses

en-us

34:03

FH25: Commercialising Health Tech and Deeptech, with...

pharmaphorum Podcast ·

2025/10/01

This year marks the 10th anniversary of Frontiers Health. In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with commercial strategy expert Pilar Fernández Hermida, founder of i-Expand, a commercial strategy firm focused on assisting Health Tech and Deeptech companies grow and monetise. Fernández Hermida shares her favourite memory from the conference’s past decade, and discusses commercialisation of new technologies, such as advanced therapies and

en-us

11:57

Agentic AI, culture shifts, and commercialisation...

pharmaphorum Podcast ·

2025/09/30

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Anthony Cilento, vice president, data science & customer insights, at Bayer, in a post-Axtria Ignite 2025 discussion on the conference and agentic AI more generally. Cilento speaks to the advancement from GenAI to agentic AI, what’s changed for his own team in this regard and what’s required by way of a culture shift more generally, as well as speaking to the changes necessary in the advanced therapies space when it comes to

en-us

19:28

FH25: On patient access and equity, with Roberta Sarno

pharmaphorum Podcast ·

2025/09/29

This year marks the 10th anniversary of Frontiers Health. In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with founder, director, and global health advisor at D-Health Consulting, Roberta Sarno. Sarno is also director of the APAC Liver Disease Alliance, and consultant on digital health APAC policy at the American Telemedicine Association, as well as advisor to the Asia Pacific Medical Technology Association. Sarno discusses her favourite memory from

en-us

11:25

FH25: On healthcare innovation with Gary Monk

pharmaphorum Podcast ·

2025/09/24

This year marks the 10th anniversary of Frontiers Health.In another episode of our limited Frontiers Health series of the pharmaphorum podcast, we speak with healthcare innovation consultant Gary Monk. Monk shares his favourite memory from the conference’s past decade, and discusses its ethos, as well as how his work at the moment aligns with that. Explore this Frontiers Health conversation and others - and find out how to attend the conference - here.

en-us

11:04

FH25: The art of connection at Frontiers Health with...

pharmaphorum Podcast ·

2025/09/19

Frontiers Health marks its 10th anniversary this year, celebrating a decade of innovation, collaboration, and the connections that drive progress.In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Aline Noizet, founder of Digital Health Connector – a phrase that she says encapsulates both her personal mission and her 15 years of experience in the industry. Noizet has built her career on connecting emerging start-ups

en-us

35:41

Policy in Focus: Trump’s Most Favoured Nations drug...

pharmaphorum Podcast ·

2025/09/18

In Donald Trump's first presidential term, he spoke a lot about "Most Favoured Nations" pricing for pharmaceuticals - that is, bringing the prices that Americans pay for drugs in line with prices paid around the world. In his first term, all that talk didn't amount to much. But this time around the pharma industry is taking the President much more seriously. In today's pharmaphorum podcast, host Jonah Comstock speaks with Alice Valder Curran, a partner at Hogan Lovells and our go-to expert on US

en-us

12:54

FH25: Exploring the intersection of patients, HCPs,...

pharmaphorum Podcast ·

2025/09/17

Frontiers Health is back, and celebrating 10 years of innovation, conversation, and collaboration. In this episode of our Frontiers Health limited series of the pharmaphorum podcast, Deep Dive editor Eloise McLennan speaks with Denise Silber, founder of Basil Strategies and Doctors 2.0. Having spent more than two decades working at the intersection of healthcare professionals, patients, and technology, Silber has had a front row seat to the evolution of digital tools in the sector. From the

en-us

10:39

Doing good in people’s lives: Amy Burroughs discusses...

pharmaphorum Podcast ·

2025/09/11

Chronic myeloid leukaemia (CML) is a unique disorder in the rare disease sector because there are multiple approved therapies for patients and, in the US alone, the prevalence of CML is expected to triple by 2040.In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Amy Burroughs, CEO of Terns Pharmaceuticals, about available treatments for CML, the potential of allosteric TKIs, and the wider oncological landscape today. You can also listen to episode 205a of the pharmaphorum

en-us

295 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter